Laurus Labs: Sustained Growth and Strategic Expansion in Q3 & 9M FY26

Laurus Labs Limited, a prominent research-driven pharmaceutical and biotechnology company, has reported a robust financial performance for the third quarter and nine months ended December 31, 2025 (9M FY26). The company showcased significant growth across key financial metrics, underscoring its strategic execution and operational efficiency. For the nine-month period, Laurus Labs achieved total revenues of ₹5,001 crores, marking an impressive 30% year-on-year growth. This strong top-line performance translated into substantial profitability, with EBITDA soaring by 104% to ₹1,303 crores and Net Profit witnessing a remarkable 388% increase to ₹610 crores. The company's EBITDA margin expanded by 9.4 percentage points to 26.1%, driven by an improved product mix and enhanced operational leverage. The Return on Capital Employed (ROCE) also showed a progressive improvement, reaching 18.5%.

The growth narrative was largely fueled by the Contract Development and Manufacturing Organization (CDMO) division, which demonstrated strong momentum and a healthy 43% growth in 9M FY26. This was complemented by a robust performance in the Generics division, which grew by 26%. Within Generics, both the Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) segments contributed significantly, primarily benefiting from increased volumes. The company's ARV business, a cornerstone of its generics portfolio, continued to show stability and increased market share in both API and formulations, with revenues currently estimated at ₹2,600 plus or minus ₹200 crores. Management emphasized that the strong Q3 performance, particularly in generics, is sustainable, supported by additional capacities and new product launches in key markets.

Strategic Investments and Capacity Expansion

Laurus Labs continues its strategic investments to expand its manufacturing network and niche capabilities, with a significant portion of its CAPEX directed towards growth projects. The company reported a 9M CAPEX of ₹735 crores, representing 15% of its revenues, and projects an overall CAPEX of approximately ₹1,000 crores for both FY26 and FY27. Key initiatives include ongoing investments in commercial-scale peptides manufacturing to support pipeline opportunities, with qualification expected during the current calendar year. The company has also operationalized a gene therapy/antibody-drug conjugate (ADC) process development lab in Hyderabad, with the cGMP facility build on track, although meaningful revenues from these advanced modalities are not anticipated in the next two years.

In a move to bolster its Finished Dosage Forms (FDF) capacity, Laurus Labs increased its capital in the KRKA Pharma India Joint Venture by ₹49 crores, with both partners collectively investing ₹100 crores. Phase-1 of this facility expansion is expected to be completed by mid-2027, with revenues projected to commence from the next financial year. Furthermore, a second GMP facility in Navi Mumbai for cell therapy is scheduled for commissioning by March 2026, which will add 2,500 annual treatment capacity, supporting the sustained demand for NexCAR19. The construction of a commercial-scale microbial fermentation facility in Vizag is also progressing as planned, with Phase-1 capacity of over 400 kiloliters expected to be operational by the end of 2026.

Quality, ESG, and Outlook

Laurus Labs maintains a strong focus on global quality standards, successfully undergoing close to 110 quality audits by multiple regulatory agencies and customers in 9M FY26 without any critical observations. The company also achieved an impressive 2025 S&P Global ESG score of 81 out of 100 points, reflecting its commitment to sustainable development and ethical business practices. This score represents a 10 percentage point increase over 2024, highlighting continuous improvement in ESG performance.

Looking ahead to FY26, Laurus Labs is well on track to deliver healthy operational growth. The management expects underlying EBITDA margins to remain higher, driven by better asset utilization and an optimized product mix, while maintaining a strong focus on operational excellence. The company's disciplined approach to capital allocation, prioritizing investments in high-value business segments, is expected to drive near and long-term growth and enhance shareholder returns. Despite the inherent lumpiness in some CDMO programs and the muted performance in the Bio division in Q3, the company expresses confidence in its long-term growth trajectory, supported by its integrated 'D & M' platform and expanding capabilities to support global customers.